The challenges of defining sample adequacy in an era of HPV based cervical screening.

[1]  J. Berkhof,et al.  Experience with HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the Netherlands. , 2019, Preventive medicine.

[2]  C. Kennedy,et al.  Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis , 2019, BMJ Global Health.

[3]  S. Temin,et al.  Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses , 2018, British Medical Journal.

[4]  P. Castle,et al.  Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. , 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[5]  F. Bray,et al.  Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. , 2016, The Lancet. Global health.

[6]  E. Lynge,et al.  HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system , 2014, BMC Infectious Diseases.

[7]  J. Peto,et al.  The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. , 2014, Health technology assessment.

[8]  E. Lynge,et al.  Prevalence of Human Papillomavirus in 5,072 Consecutive Cervical SurePath Samples Evaluated with the Roche Cobas HPV Real-Time PCR Assay , 2013, PloS one.